Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesUrologyPacificSource BPH Prior Auth Policy | OpenPayer
    Ask Trek AI about this page
    CurrentPacificSource Community SolutionsPolicy N/A

    Benign Prostatic Hyperplasia (BPH) Treatments

    Customize your policy alerts

    Sign up for all pacificsourcecommunitysolutions policy alerts

    Know when pacificsourcecommunitysolutions releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Coverage and medical-necessity criteria for selected BPH treatments for Commercial, Medicare, and Medicaid members in Idaho, Montana, Oregon, and Washington.

    Policy Summary
    PayerPacificSource Community Solutions
    PolicyBenign Prostatic Hyperplasia (BPH) Treatments
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateDecember 31, 2020
    Next Review DateDecember 1, 2026
    Key ActionObtain prior authorization and document failure or intolerance of BPH medication management for at least 3 months before requesting any of the three covered treatments.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    3Treatments with defined medical-necessity criteria
    45+ yearsMinimum age for prostatic urethral lift
    50+ years

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Minimum age for water vapor therapy
    6Listed lower urinary tract symptoms
    6Treatments or tests designated experimental, investigational, or unproven

    Covered Treatments and Medical Necessity Criteria

    Initial therapy: prostatic urethral lift

    Covered when ALL of the following are met; the lower urinary tract symptom requirement may be satisfied by ANY one of the listed symptoms.

    Required criteria

    • Member and treatment criteria

      • Member is at least 45 years old.
      • Prostate volume is not greater than 100 mL based on ultrasound imaging.<= 100 mL
      • The median lobe of the prostate is not obstructed.
      • Peak flow rate (Qmax) is less than or equal to 12 mL/second.Qmax <= 12 mL/second
      • The member has intolerance to or failure of medication management for BPH symptoms for 3 months or longer.Medication management >= 3 months

        Examples include alpha blockers, PDE5 inhibitors, finasteride, and dutasteride.

    • At least one qualifying lower urinary tract symptom

      • Urinary frequency
      • Urgency
      • Nocturia
      • Weak stream
      • Straining
      • Intermittency

    Initial therapy: transurethral water vapor therapy

    Covered when ALL of the following are met.

    Required criteria

    • Member is at least 50 years old.
    • ALL of the following

      • International Prostate Symptom Score (IPSS) is at least 13.IPSS >= 13
      • Maximum urinary flow rate (Qmax) is less than or equal to 15 mL/second, with voided volume no greater than 125 mL.Qmax <= 15 mL/second; voided volume <= 125 mL
      • The member has intolerance to or failure of medication management for BPH symptoms for 3 months or longer.

    Initial therapy: waterjet tissue ablation

    Covered when ALL of the following are met.

    Required criteria

    • Treatment is for lower urinary tract symptoms secondary to benign prostatic hyperplasia (BPH).
    • Prostate gland volume is less than or equal to 150 mL based on ultrasound imaging.<= 150 mL
    • International Prostate Symptom Score (PPSS) is at least 13.PPSS >= 13
    • The member has intolerance to or failure of medication management for BPH symptoms for 3 months or longer.Medication management >= 3 months

      Examples include alpha1-adrenergic antagonists, 5-alpha-reductase inhibitors, or combination medication therapy.

    The following are considered experimental, investigational, and unproven: temporary removable or biodegradable prostatic urethral stents; transurethral balloon dilation, including the Optilume BPH Catheter System; the Tulsa Procedure or transurethral ultrasound ablation; prostatic arterial embolization for BPH; and the UroCuff/Penile Cuff test. These services are not covered under this policy.

    Waterjet tissue ablation is considered experimental, investigational, and unproven for indications other than treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia under the policy’s stated coverage criteria.

    For Medicaid, codes 53855 and C9769 are listed under Excluded Services E2 of the Oregon Health Plan Prioritized List because of insufficient evidence of effectiveness. Coverage determinations must also follow applicable Oregon Administrative Rules, Guideline Note 145, EPSDT requirements, and case-by-case EPSDT medical-necessity and medical-appropriateness review when applicable.

    Coding and Clinical Thresholds

    Coding Informationmixed
    37242Vascular embolization or occlusion, inclusive of all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary
    51721Insertion of transurethral ablation transducer for delivery of thermal ultrasound for prostate tissue ablation, including suprapubic tube placement during the same session and placement of an endorectal cooling device, when performed
    52284Cystourethroscopy, with mechanical urethral dilation and urethral therapeutic drug delivery by drug-coated balloon catheter for urethral stricture or stenosis, male, including fluoroscopy, when performed
    52441Cystourethroscopy with transurethral resection or incision of ejaculatory ducts
    52442Each additional permanent adjustable transprostatic implant
    52443Cystourethroscopy with initial transurethral anterior prostate commissurotomy with a nondrugcoated balloon catheter followed by therapeutic drug delivery into the prostate by a drugcoated balloon catheter, including transrectal ultrasound and fluoroscopy, when performed
    52597Transurethral robotic-assisted waterjet resection of prostate, including intraoperative planning, ultrasound guidance, control of postoperative bleeding, complete, including vasectomy, meatotomy, cystourethroscopy, urethral calibration and/or dilation, and internal urethrotomy, when performed
    53854Transurethral destruction of prostate tissue; by radiofrequency generated water vapor thermotherapy
    53855Insertion of a temporary prostatic urethral stent, including urethral measurement
    53865Cystourethroscopy with insertion of temporary device for ischemic remodeling (i.e., pressure necrosis) of bladder neck and prostate
    1–10 of 19
    1/2
    Medicaid Excluded Services E2HCPCSNot Covered
    53855Excluded Services E2 code for Medicaid; insufficient evidence of effectiveness
    C9769Excluded Services E2 code for Medicaid; insufficient evidence of effectiveness
    Prostatic Urethral Lift — Prostate Volume
    TreatmentProstatic urethral lift
    Prostate volume thresholdNot greater than 100 mL
    Measurement methodBased on ultrasound imaging
    Prostatic Urethral Lift — Peak Flow Rate
    TreatmentProstatic urethral lift
    Peak flow rate thresholdQmax less than or equal to 12 mL/second
    Measure

    Authorization and Provider Requirements

    Prior Authorization

    Prostatic Urethral Lift: Prior Authorization Required

    Prior authorization is required for prostatic urethral lift. Coverage is medically necessary for lower urinary tract symptoms due to BPH only when all listed criteria are met.

    • Member is at least 45 years old.
    • Prostate volume is ≤100 mL based on ultrasound imaging.
    • Median lobe of the prostate is not obstructed.
    • Peak flow rate (Qmax) is ≤12 mL/second.
    • Member has intolerance to or failure of BPH medication management for 3 months or longer, such as alpha blockers, PDE5 inhibitors, finasteride, or dutasteride.
    • Lower urinary tract symptoms include one or more of: urinary frequency, urgency, nocturia, weak stream, straining, or intermittency.
    Prior Authorization

    Transurethral Water Vapor Therapy: Prior Authorization Required

    Prior authorization is required for transurethral water vapor therapy, including the Rezum system procedure. Coverage is medically necessary for lower urinary tract symptoms associated with BPH only when all listed criteria are met.

    Condition Overview

    Benign prostatic hyperplasia (BPH) is a noncancerous enlargement of the prostate that can compress the urethra and cause lower urinary tract symptoms. Symptoms may include frequency, urgency, nocturia, weak stream, straining, intermittency, urinary retention, or loss of bladder control. This policy addresses minimally invasive and surgical treatments for these symptoms, including prostatic urethral lift, transurethral water vapor therapy, and waterjet tissue ablation.

    Treatment Definitions

    Prostatic Urethral Lift
    ProcedureA treatment for benign prostatic hyperplasia (BPH) symptoms using implants
    MechanismImplants separate enlarged prostate lobes
    Intended effectReduce pressure on the urethra
    Transurethral Water Vapor Therapy
    ProcedureDelivers sterile water vapor directly into hyperplastic prostate tissue
    MechanismHeat is released as the vapor condenses
    Tissue effectCauses cell death and may improve BPH symptoms
    Policy Summary
    PayerPacificSource Community Solutions
    PolicyBenign Prostatic Hyperplasia (BPH) Treatments
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateDecember 31, 2020
    Next Review DateDecember 1, 2026
    Key ActionObtain prior authorization and document failure or intolerance of BPH medication management for at least 3 months before requesting any of the three covered treatments.
    SourceLink
    On This Page
    Covered Treatments and Medical Necessity CriteriaCoding and Clinical ThresholdsAuthorization and Provider RequirementsCondition OverviewTreatment Definitions
    Medication management >= 3 months

    Examples include alpha blockers, PDE5 inhibitors, finasteride, and dutasteride.

  1. Prostate gland volume is estimated at 30 to 100 mL or grams in weight by clinical or ultrasound assessment.30-100 mL or grams
  2. Peak urinary flow rate (Qmax)
    Water Vapor Therapy — IPSS
    TreatmentTransurethral water vapor therapy
    Symptom scoreInternational Prostate Symptom Score (IPSS)
    IPSS thresholdGreater than or equal to 13
    Water Vapor Therapy — Flow Rate and Voided Volume
    TreatmentTransurethral water vapor therapy
    Peak flow rate thresholdQmax less than or equal to 15 mL/second
    Voided volume thresholdNo greater than 125 mL
    Water Vapor Therapy — Prostate Volume
    TreatmentTransurethral water vapor therapy
    Prostate volume range30 to 100 mL
    Alternative weight measure30 to 100 grams
    Assessment methodClinical or ultrasound assessment
    Waterjet Tissue Ablation — Prostate Volume
    TreatmentWaterjet tissue ablation
    Prostate volume thresholdLess than or equal to 150 mL
    Measurement methodBased on ultrasound imaging
    Waterjet Tissue Ablation — Symptom Score
    TreatmentWaterjet tissue ablation
    Symptom scoreInternational Prostate System Score (PPSS)
    PPSS thresholdGreater than or equal to 13
    • Member is at least 50 years old.
    • Symptoms persist despite maximal medical management.
    • International Prostate Symptom Score (IPSS) is ≥13.
    • Maximum urinary flow rate (Qmax) is ≤15 mL/second, with voided volume no greater than 125 mL.
    • Member has intolerance to or failure of BPH medication management for 3 months or longer, such as alpha blockers, PDE5 inhibitors, finasteride, or dutasteride.
    • Prostate gland volume is 30–100 mL (or grams in weight), estimated by clinical or ultrasound assessment.
    Prior Authorization

    Waterjet Tissue Ablation: Prior Authorization Required

    Prior authorization is required for waterjet tissue ablation, including the AquaBeam System. Coverage is medically necessary for lower urinary tract symptoms secondary to BPH only when all listed criteria are met.

    • Prostate gland volume is ≤150 mL based on ultrasound imaging.
    • International Prostate Symptom Score (IPSS/PPSS) is ≥13.
    • Member has intolerance to or failure of BPH medication management for 3 months or longer, including α1-adrenergic antagonists, 5α-reductase inhibitors, or combination medication therapy.
    Step Therapy

    Medication Management Required Before Procedure

    Before requesting any of the covered BPH procedures above, document intolerance to or failure of medication management for BPH symptoms for 3 months or longer. This medication-management requirement applies to prostatic urethral lift, transurethral water vapor therapy, and waterjet tissue ablation.

    • Document the medication trial, duration, response, and reason for intolerance or failure.
    • Examples include alpha blockers or α1-adrenergic antagonists, PDE5 inhibitors, finasteride, dutasteride, 5α-reductase inhibitors, or combination medication therapy.
    • For transurethral water vapor therapy, the member must remain symptomatic despite maximal medical management.
    Denial Risk

    Experimental, Investigational, or Unproven Services

    The following services are considered experimental, investigational, and unproven and are not covered under the policy. Requests may be denied as experimental, investigational, or unproven.

    • Temporary removable or biodegradable prostatic urethral stents.
    • Transurethral Balloon Dilation (TUDP), including the Optilume BPH Catheter System.
    • Tulsa Procedure or transurethral ultrasound ablation.
    • Prostate Arterial Embolization (PAE), also called transcatheter embolization, for BPH.
    • UroCuff test, also called the Penile Cuff test; it remains E/I/U and is not reviewed annually by the NTOC Committee unless requested.
    • PacificSource Community Solutions and PacificSource Medicare require items on the E/I/U list to be reviewed under medical necessity review guidelines; consult the Clinical Criteria Used in UM Decisions and Medical Necessity Reviews policies for coverage and criteria hierarchy.
    Denial Risk

    Waterjet Ablation Outside Covered Indication

    Waterjet tissue ablation is considered experimental, investigational, and unproven for all other indications outside the covered BPH indication and criteria. Requests for waterjet ablation that do not meet the covered indication or required criteria may be denied.

    • Covered indication: lower urinary tract symptoms secondary to BPH, subject to prior authorization and all required criteria.
    • All other indications are experimental, investigational, and unproven.
    Billing Rule

    Medicaid Excluded Codes and Review Rules

    For Medicaid members, codes 53855 and C9769 are excluded because of insufficient evidence of effectiveness. Apply the applicable Oregon Medicaid rules and review requirements when processing BPH treatment requests.

    • Excluded Services E2 of the OHP Prioritized List applies to codes 53855 and C9769.
    • PacificSource Community Solutions follows OAR 410-141-3820, 410-141-3825, 410-141-3830, and Guideline Note 145 of the OHP Prioritized List for BPH treatment coverage.
    • EPSDT beneficiaries require case-by-case review for EPSDT medical necessity and medical appropriateness under OAR 410-151-0002 and OAR 410-151-0001; Guideline Note 145 and Excluded Services E2 may inform the review.
    • Requests using unlisted codes are subject to the Unlisted and Unspecified Procedure Codes policy.
    Waterjet Tissue Ablation
    ProcedureUses electromechanical precision and live ultrasound to ablate prostatic glandular tissue
    Ablation methodA high-velocity sterile saline stream is delivered without producing heat
    After ablationAblated tissue is removed and a laser beam is used to cauterize the excised area